Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by М. V. Davydovskaya
Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma
Malignant tumours
Related publications
Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia
OncoTargets and Therapy
Oncology
Pharmacology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma
Blood and Lymphatic Cancer: Targets and Therapy
Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin
British Journal of Haematology
Hematology
A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Journal of Health Economics and Outcomes Research
Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Pharmacoeconomic Analysis of Brentuximab Vedotin Therapy in Relapsed or Refractory Cd30+ Systemic Anaplastic Large Cell Lymphoma in Patients Over 18 Years of Age: Health Budget Impact Analysis
PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology
